Errata: Vol. 64, No. 28

Weekly

July 31, 2015 / 64(29);806

In the report, "Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015," on page 755, the second sentence should read, "MoLHSA partnered with Gilead Sciences, a pharmaceutical manufacturer that agreed to support the program by providing an initial 5,000 courses of the antiviral medications sofosbuvir (Sovaldi), followed by 20,000 treatment courses of ledipasvir-sofosbuvir (Harvoni) annually at no cost.